CN105497205A - Medicine for interventionally treating diabetes - Google Patents
Medicine for interventionally treating diabetes Download PDFInfo
- Publication number
- CN105497205A CN105497205A CN201410557099.5A CN201410557099A CN105497205A CN 105497205 A CN105497205 A CN 105497205A CN 201410557099 A CN201410557099 A CN 201410557099A CN 105497205 A CN105497205 A CN 105497205A
- Authority
- CN
- China
- Prior art keywords
- diabetes
- accounts
- fructus mume
- fructus
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses medicine for interventionally treating diabetes. The medicine comprises, by weight percentage, 50-79% of prepared fructus mume and 10-16% of mulberry, wherein the prepared fructus mume and the mulberry are effective constituents. Animal experiments show that the medicine for interventionally treating the diabetes can effectively lower the blood sugar level of rats with the diabetes and reduce area under a glucose tolerance experimental curve.
Description
Technical field
The present invention relates to a kind of medicine of therapeutic intervention diabetes, being specifically related to is the pharmaceutical composition of the therapeutic intervention diabetes of effective ingredient containing Fructus Mori and Fructus Mume processed.
Background technology
Diabetes (diabetes) be multiple virulence factor act on body cause hypoinsulinism, insulin resistant etc. and cause a series of metabolism disorder syndrome such as sugar, protein, fat, water and eletrolytes, be main feature clinically with hyperglycemia.The overall prevalence of the current diabetes of China reaches 9.7%.The same period prediabetes prevalence up to 15.5%.The reckoning made according to survey result shows China's total patient of diabetes patient number and reaches more than 9,000 2 hundred ten thousand, and prediabetes number reaches more than 100,000,000 4 thousand 8 hundred ten thousand.Diabetes be islet β cell insulin definitely or relative deficiency, companion or do not accompany insulin resistant.Onset diabetes process is slow, and mechanism is illustrated not yet completely.
The treatment of diabetes almost needs to run through lifelong, and treatment mainly contains insulin, chemicals and Chinese medicine etc., and other not yet full ripe method has islet transplantation and stem-cell therapy.Although method is many, all diabetes can not be cured, and the sickness rate of diabetes is in the situation that rises fast.Its main cause occurs in the process of development in diabetes, and islet beta cell function damage exists before onset diabetes, and this damage becomes irreversible along with increasing the weight of of degree.Unfortunately during onset diabetes, islet beta cell function damage is substantially in irreversible state, and the treatment of diabetes often just starts after diabetes occur.The current incurable main cause of diabetes that Here it is.
Carry out therapeutic intervention before there are some researches show onset diabetes and can effectively stop or delay the generation of this disease, but problem is, due to all many-side restrictions such as Medical Ethics and poisonous side effect of medicine, existing Remedies for diabetes can not be used for the premorbid Primary preventive intervention treatment of people.This also new is inserted into a little for the study on prevention of diabetes provides one, namely finds new safe drugs, before onset diabetes, islet beta cell function damage carry out Primary preventive intervention treatment in early days.
In this, Chinese medicine, through the practical application of several thousand, has been proved to be effective and rare side effect, can be used for the conditioning of body function, health-preserving functions such as health care and without medical ethics problems.Therefore Chinese medicine can play irreplaceable important function in the Primary preventive intervention treatment of diabetes.Fructus Mume processed is as a kind of Chinese medicine, sour in the mouth, micro-puckery, tool astringe the lung promote the production of body fluid, the merit of astringing intestine to stop diarrhea relieving colic caused by ascaris, due to energy exciting salivary secretion, promoting the production of body fluid to quench thirst, be commonly used to quench one's thirst (as the diabetes) for the treatment of thirsty polydipsia, in treatise on Febrile Diseases 326, just recite the treatment of wumei pills for " quenching one's thirst ", and improve the symptoms such as patient is easy hungry, thirsty, fatigue and weak.Containing abundant organic acid in Fructus Mume, as citric acid, malic acid, oxalic acid, glycolic, Fumaric acid etc., the mainly citric acid that wherein content is higher and malic acid; In addition, also the trace element such as chemical composition and Fe, Mg, Cu, Zn such as flavonoid, terpenoid, saccharide are contained in Fructus Mume.In experimentation in recent years, also from Fructus Mume, isolation identification has gone out 2 alkaloid compounds (2,2,6,6-tetramethylpiperidone, tert butyl urea), and superoxide dismutase (SOD); The vitamin content of Fructus Mume is also suitable abundant, and it contains the vitamin C approximate with other fruit and vitamin B1, but the content of vitamin B2 is hundreds of times more than of other fruit, reaches 5.6mg/100g.These abundant chemical compositions make Fructus Mume have the useful effect of heavy multipair human body.
Research display, in the control experiment of Fructus Mume and metformin, the glycemic control of Fructus Mume and metformin group is all right, the equal < 7.0mmol/L of fasting glucose, the equal < 10.0mmol/L of post-prandial glycemia; Glycolated hemoglobin (HbAlc) level of Fructus Mume group drops to 6.78% from 7.66%, the glycated hemoglobin levels of metformin group drops to 6.76% from 8.23%, no difference of science of statistics, describe Fructus Mume and can improve T2DM rat glycated hemoglobin levels, and there is obvious hypoglycemic activity.Meanwhile, the effect that Fructus Mume has reparation to impaired beta Cell of islet and regenerates, makes islet beta cell function recover and stimulates excreting insulin.
Fructus Mori is the mellow fruit favour of moraceae plants Mulberry.The traditional Chinese medical science is thought " Fructus Mori sweet in the mouth is cold in nature, can nourishing the liver and kidney, nourishing blood to expel wind, calm the nerves nourish heart, slow down aging." Fructus Mori is rich in fructose, the acid of ammonia tomb, vitamin, phospholipid and mineral etc., is the high-quality source of ascorbic first-class source, potassium.Fructus Mori is the same with Folium Mori, has blood sugar lowering, blood fat reducing and antioxidation; All there is from the isolated 25 kinds of polyphenolic substances of Fructus Mori ethyl acetate extract the activity of significant Inhibiting α-glucosidase and scavenging free radicals, show Fructus Mori and there is antioxidation.
Although show Fructus Mume in above prior art and Fructus Mori may have hypoglycemic effect respectively, but in prior art, do not provide the using method by Fructus Mume and Fructus Mori.Especially, because be rich in fructose in Fructus Mori, when not understanding its mechanism and concrete effective ingredient, the fructose be rich in after taking without authorization will make the blood glucose generation rising sharply of diabetics, be unfavorable for the health of patient on the contrary.Moreover be rich in citric acid, malic acid and succinic acid in Fructus Mume, polyphagia is damage tooth not only, also can damage taste.
At the antecedent intervention treatment stage of diabetes, it is one of problem proposed by the invention that the blood glucose how effectively controlling patient does not have side effects, meanwhile, in order to satisfied difference takes the needs of crowd, provide a kind of effective and cheap pharmaceutical composition also an object of the present invention.
Based on problem existing in prior art; the medicine that this patent is applied for is a kind of medicine with function of blood sugar reduction refined with pure natural plant Fructus Mume, Fructus Mori hybrid process; to the damage of prevention beta Cell of islet, protection islet beta cell function has special curative effect.Simultaneously, this Fructus Mume, Fructus Mori compositions, by suitable proportioning, eliminate side effect when these two kinds of Chinese crude drugs are taken separately, as the medicine of antecedent intervention treatment diabetes, while achieving beyond thought therapeutic effect, conveniently also there is great practicality at cost and price.
Summary of the invention
Technical problem to be solved by this invention is as diabetes provided a kind of pharmaceutical composition of therapeutic intervention diabetes before morbidity.For solving the problem, the present inventor has found a kind of pharmaceutical composition of therapeutic intervention diabetes through concentrating on studies, it is characterized in that, is effective ingredient containing Fructus Mume and Fructus Mori.
The pharmaceutical composition of a kind of therapeutic intervention diabetes of the present invention, preferred effective ingredient account for described pharmaceutical composition gross weight percentage this be: described Fructus Mume accounts for 50% ~ 79%, and described Fructus Mori accounts for 10% ~ 16%.
The pharmaceutical composition of a kind of therapeutic intervention diabetes of the present invention, more preferably described Fructus Mume accounts for 79%, and described Fructus Mori accounts for 16%.
The pharmaceutical composition of a kind of therapeutic intervention diabetes of the present invention, also comprises pharmaceutically acceptable carrier and/or excipient.
The present invention also provides the application of a kind of pharmaceutical composition in therapeutic intervention diabetes, it is characterized in that, described pharmaceutical composition contains Fructus Mume and Fructus Mori is effective ingredient.
The present invention also provides the application of a kind of pharmaceutical composition in therapeutic intervention diabetes, and the percentage ratio that preferred described effective ingredient accounts for described pharmaceutical composition gross weight is: described Fructus Mume accounts for 50% ~ 79%, and described Fructus Mori accounts for 10% ~ 16%.
The present invention also provides the application of a kind of pharmaceutical composition in therapeutic intervention diabetes, and more preferably described Fructus Mume accounts for 79%, and described Fructus Mori accounts for 16%.
Accompanying drawing explanation
Fig. 1: the distillate of embodiment of the present invention one example extracts figure.
Fig. 2: the present composition has the comparison diagram reducing blood glucose in diabetic rats effect.
Fig. 3: the present composition has the comparison diagram of the effect reducing diabetes rat glucose tolerance test area under curve.
Detailed description of the invention
To embodiments of the present invention be illustrated below, however embodiments of the present invention not limit by following detailed description of the invention.
1. the separated and collected of Fructus Mori and Fructus Mume volatile oil
Volatile oil, has another name called quintessence oil, is the general name of the oily liquids not miscible with water that a class can obtain with vapor distillation.The common method extracting volatile oil from the fresh fruit or its quick freezing and cold preserving fresh fruit of Fructus Mori and Fructus Mume has the way of distillation, solvent extraction method, milling process, supercritical fluid extraction method.Adopt the steam distillation that general traditional medicine volatile oil is taked in present embodiment, concrete grammar is conventional method, also can adopt the extracting method described in the patent documentations such as CN201940071U, CN2928228Y, CN2686690Y.
From fresh fruit, volatile oil is extracted except above-mentioned, can also be dry by various drying mode by raw material, then the conventional method adopted by this area prepares Chinese medical concrete, as long as when not destroying raw material main constituent, the optional main component extracting Fructus Mori and Fructus Mume in any way of the present invention, wherein preferable separate collects volatile oil, because sugar and other side effect composition can be reduced in rational scope in volatile oil.
2. the preparation of compositions
By the above-mentioned volatile oil of separated and collected from Fructus Mori and Fructus Mume respectively, mix according to specific ratio, compositions formulated stock solution.Also according to demands different clinically, make pill, powder, tablet, suppository, granule, membrane, capsule, microcapsule, drop pill, aerosol, injection, unguentum, medicated wine, syrup, oral solution, gel or liposome.Detailed description of the invention can perform in version standard according to Chinese Pharmacopoeia for 2000.
3. the effect detection of the present composition
3.1 animal origins and model preparation
Healthy male SD rat, in 2 months ages of Mus, body weight 150 ~ 200g, is provided by Zhejiang Province's Experimental Animal Center.The front animal of experiment is all placed in laboratory and conforms one week, freely drink water and standard rat chow nursing, keep clean in cage, room temperature controls at 23 ± 2 DEG C, natural lighting (supporting in University Of Ningbo's medical college Experimental Animal Center), relative humidity is 60% ~ 70%.6 rats also feed with normal diet surrounding as Normal group first random selecting.All the other rats high glucose and high fat feedstuff (15% Adeps Sus domestica, 20% sucrose, 13 yolk powders, 2% sodium cholate, 50% normal diet) is fed after surrounding with the dosage of 30mg/kg (1 week 1 time, continuous 2 weeks) disposable celiac injects 1% streptozotocin (STZ, Sigma Co., USA, lot number: SO130-1g) citrate buffer solution (with pH be 4.2 0.1mol/L sodium citrate buffer solution preparation, now with the current), Normal group synchronously injects the normal saline of equivalent in tail vein.
After two weeks, the rat of molding is cut tail and gets blood survey fasting glucose and random blood sugar, select fasting blood sugar (FBG) >=7.8mol/L, the rat of random blood sugar value >=11.1mol/L 12, and be divided into diabetic model group 6 at random, every day gavage 0.9% normal saline; Positive drug control group 6, every day gavage Fructus Mume Fructus Mori preparation.
3.2 intervening measure
Hop to it after diabetes model is successful pretreat.5g/kg dosage gastric infusion pressed by Fructus Mume Fructus Mori preparation, every day 1 time, continuous gavage 4 weeks.Normal group synchronously gives the normal saline of equivalent, continuous gavage 4 weeks.
Present composition experimental group according to the dosage gavage of 200ml/kg, the normal saline of Normal group and negative control group gavage equal solvent.Wherein when configuring compositions of the present invention, the remaining part outside Fructus Mori and Fructus Mume distillate is distilled water.Gavage interval is 12 hours.
The Acquire and process of 3.3 specimen
After treatment terminates, each group rat all surveys fasting glucose, weighs, carry out relative recording, then promptly rat is directly cut off side femoral artery and causes its death, then carries out dissection to rat and gets pancreas rapidly, 4 DEG C of normal saline flushings totally fix 24h with 4% formaldehyde, distilled water immersion 4h afterwards.Take out conventional gradients dehydration of alcohol, dimethylbenzene is transparent, paraffin embedding, LEICA2135 paraffin slicing machine serial section, and thickness 5 μm, gets 1 every 20, and each specimen gets 6, and mount respectively on the microscope slide scribbling polylysine, room temperature preservation is for subsequent use.
3.4 observation index
3.4.1 ordinary circumstance
Every day observes rats eating, drinking-water situation, urine volume, the changes such as mental status.Respectively before modeling, after modeling, after treatment, survey body weight.
3.4.2 blood sugar detection
3.4.2.1 fasting glucose and random blood sugar
Each treated animal is surveyed fasting glucose (FBG) (mmol/L) respectively before modeling, after modeling, after treatment, and surveyed a random blood sugar every 3 days, survey fasting glucose eve, Rat Fast 12h, next day, caudal vein got blood, measure fasting glucose by automatic blood glucose meter, and carry out relative recording.
3.4.2.2 oral glucose tolerance test (OGTT)
Row oral glucose tolerance test (OGTT) before modeling, after modeling, after treatment.After Rat Fast 12h, by 2g/kg dosage, by 50% glucose solution gavage, get tail vein in 0h, 0.5h, 1h, 2h and survey blood glucose.Experiment terminates rear drafting each group of rat glucose tolerance curve.
3.4.3 pathomorphology
Treatment terminates rear sacrifice of animal and wins pancreas rapidly, and after 4 DEG C of normal saline flushings are clean, 4% formaldehyde fixes 24h, distilled water immersion 4h.Conventional gradients dehydration of alcohol, dimethylbenzene is transparent, paraffin embedding, LEICA2135 paraffin slicing machine serial section, and thickness 5 μm, mounts on the microscope slide scribbling polylysine, uses the rear optical microphotograph Microscopic observation of hematoxylin-eosin staining method dyeing.
3.4.4 immunohistochemistry
Prepare the affine pure and mild antibody of HIF-1 α, instant SABC test kit, DAB colour reagent box.Get above-mentioned section to be placed in 60 DEG C of baking boxs and to examine sheet 1h, operate in strict accordance with test kit operating instruction, the conventional dewaxing of row section, distilled water immersion 2 minutes; Add 3% hydrogen peroxide at room temperature lower 10 minutes; Distillation washing 1 minute × 3 times; Section is placed in 0.01mol/L citrate buffer, and microwave heating is boiling extremely, power-off 15 minutes, again natural cooling after ebuillition of heated; Add 0.02mol/LPBS and wash 1 minute × 3 times; Add 5%BSA antigen blockade, lower 20 minutes of room temperature, gets rid of surplus liquid; Drip primary antibodie (1: 100) dilution, hatch 1 hour for 37 DEG C; 0.02mol/LPBS washes 2 minutes × 3 times; Drip biotinylation two to resist, hatch 20 minutes for 37 DEG C; 0.02mol/LPBS washes 2 minutes × 3 times; Drip the chain enzyme avidin of horseradish peroxidase-labeled, hatch 20 minutes for 37 DEG C; 0.02mol/LPBS washes 5 minutes × 4 times; DAB develops the color, and controls the response time under mirror; Haematoxylin redyes 10 seconds, tap water; Dehydration, transparent, resinene mounting.Light Microscopic observation, specific stain is lamellar brown yellow granule.The negative blank replacing primary antibodie with 0.1mol/LPBS liquid is all synchronously set up to often criticizing dyeing.Under optical microscope (400 times), often open section Stochastic choice 4 visuals field, count the positive cell number in each visual field respectively, finally do this comparatively with the mean of each group.
3.4.5 immunofluorescence dyeing
10min fixes in tissue freezing section's room temperature acetone (cold acetone), drip thereon with the immune serum that capillary burette is drawn through suitably dilution after fixing, be placed in the humidity that colouration box keeps certain, 37 DEG C of effect 30min, then twice is washed with 0.01mol/1pH7.2PBS, 10min, with sucking or drying up remaining liquid; Drip indirect fluorescent antibody (the white fluorescent antibody of γ-ball egg 1 as anti-human in rabbit etc.) again, then wash twice, 10min with PBS, dyeing 30min, 37 DEG C, buffer salt washes twice 10min, stirs, the sealing of buffering glycerol, uses laser confocal microscope Microscopic observation.Contrast dyeing: replace immune serum with normal rabbit serum or human serum, then dye by method, result should be negative.
3.4.6RT-PCR
Concentration is surveyed after tissue extraction RNA, A1/A2 should between 1.8-2.0, by of short duration for RNA centrifugal after, add M-MLV reverse transcriptase 1ul, 5 × RT buffer 5ul, Oligo (dT) 18 (20mol/L) 2ul, dNTP (20umol/L) 2ul, RNA2ug, mend deionized water to 20ul volume, 42 DEG C of 1h reverse transcription reactions, 95 DEG C of 5min deactivation M-MLV, centrifugal again, 70 DEG C of heating 5min, stop above-mentioned reaction, be placed on ice, row reverse transcription reaction, strictly reaction reagent is added successively again by test kit operating instruction in PCR reaction tube, again PCR pipe is inserted PCR instrument, 95 DEG C of degeneration 5min, carry out 35 cyclic amplification reactions (94 DEG C, 1min, annealing temperature depending on primer (50-60 DEG C), 1min, 72 DEG C, 1min), then 72 DEG C of constant temperature 7min, take out PCR reaction tube, carry out electrophoresis detection to product, electrophoresis terminates rear taking-up agarose gel, is placed on gel imaging instrument lightly or imaging on ultraviolet transilluminator.Estimate the size of amplified band according to DNA molecular amount standard, electrophoresis result is formed e-file and file or take pictures by photographic system.
3.4.7Westemblot
From tissue extraction albumen also quantitatively, after 10%SDS polyacrylamide gel electrophoresis protein isolate, electricity consumption is transferred on nitrocellulose filter, the complete rear title defatted milk powder TBST buffer of transferring film is made into the concentration se al of 5%, add primary antibodie (primary antibodie TBST is diluted to debita spissitudo) after washing film and hatch 1h, add after washing film once again and resist with two of Western bis-anti-diluted horseradish peroxidase (HRP) labelling and hatch 1h, with DAB nitrite ion colour developing 1h, with the molecular weight of gel image analysis systematic analysis object tape and clean on carry out optical density value.
Embodiment
Respectively the fresh fruit (or freezing fresh fruit) of 1000g Fructus Mori and Fructus Mume is blended homogenate with blender, be placed in alembic as shown in Figure 1, after distillation, collect product of distillation.Wherein the product of distillation of Fructus Mori is 452g, and yield is 45.2%, and the product of distillation of Fructus Mume is 337g, and yield is 33.7%.
Above-mentioned product of distillation is carried out the formula of different proportion, and feed to rat model and normal rat in contrast, specific experiment example and to this such as shown in table 1.After surrounding administering transgenic terminates, add up the Evaluation of blood test value of each group of rat, with the concentration of determination of glucose oxidase serum glucose (unit is for mg/dl).
Fig. 2 display be the result of the present composition one model experiment example, each experimental group is the meansigma methods repeating for three times to test.
Wherein,
A group is the blank of normal rat
B group is the blank of diabetic model rats
C group is the blood sugar concentration of diabetic model rats after present composition therapeutic intervention
D group is take separately the diabetic model rats of Fructus Mume processed
E group is take separately the diabetic model rats of Fructus Mori
Fig. 3 shows the medicine that this patent applies for the effect reducing diabetes rat glucose tolerance test area under curve, and in figure, a is normal group, b group, c group, d group and e group are respectively diabetes blank group and different medication group, and getting Normal group is 1, and all the other in contrast.Wherein,
A group is the blank of normal rat
B group is the blank of diabetic model rats
C group is the blood sugar concentration glycosuria of diabetic model rats after present composition therapeutic intervention
D group is take separately the diabetic model rats of Fructus Mume processed
E group is take separately the diabetic model rats of Fructus Mori
The result of other embodiments of the invention and reference examples is as shown in table 1, and according to result shown in table 1, after can learning the pharmaceutical composition using invention, the technique effect obtained has:
1. with matched group mutually this, the distillate of feed separately Fructus Mume processed or Fructus Mori, although have certain inhibitory action to hyperglycemia in diabetic model rats, the blood glucose of rat but can be reduced to lower level by compositions of the present invention.
2., especially according to these routine Fructus Mume processed used in combination and Fructus Mori of the present invention, the blood sugar concentration of result display rat is controlled in the normal value between 7-10mg/dl, achieves beyond thought effect.
The blood sugar concentration of rat after 4 weeks in each experimental example of table 1. and reference examples
Claims (7)
1. a medicine for therapeutic intervention diabetes, is characterized in that, is effective ingredient containing Fructus Mume processed and Fructus Mori.
2. pharmaceutical composition as claimed in claim 1, it is characterized in that, the percentage ratio that described effective ingredient accounts for described pharmaceutical composition gross weight is: described Fructus Mume processed accounts for 50% ~ 79%, and described Fructus Mori accounts for 10% ~ 16%.
3. pharmaceutical composition as claimed in claim 2, it is characterized in that, described Fructus Mume processed accounts for 79%, and described Fructus Mori accounts for 16%.
4. the pharmaceutical composition as described in any one of Claims 1 to 4, is characterized in that, also comprises pharmaceutically acceptable carrier and/or excipient.
5. the application of pharmaceutical composition in therapeutic intervention diabetes, is characterized in that, described pharmaceutical composition contains Fructus Mume processed and Fructus Mori is effective ingredient.
6. apply as claimed in claim 5, it is characterized in that, the percentage ratio that described effective ingredient accounts for described pharmaceutical composition gross weight is: described Fructus Mume processed accounts for 50% ~ 79%, and described Fructus Mori accounts for 10% ~ 16%.
7. apply as claimed in claim 6, it is characterized in that, described Fructus Mume processed accounts for 79%, and described Fructus Mori accounts for 16%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410557099.5A CN105497205A (en) | 2014-10-15 | 2014-10-15 | Medicine for interventionally treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410557099.5A CN105497205A (en) | 2014-10-15 | 2014-10-15 | Medicine for interventionally treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105497205A true CN105497205A (en) | 2016-04-20 |
Family
ID=55705764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410557099.5A Pending CN105497205A (en) | 2014-10-15 | 2014-10-15 | Medicine for interventionally treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105497205A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107693713A (en) * | 2017-10-27 | 2018-02-16 | 北京昆达中医医学研究院 | A kind of Chinese herbal medicine drink of auxiliary hyperglycemic |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1225823A (en) * | 1998-02-12 | 1999-08-18 | 王钢柱 | Chinese medicine for treating diabetes and preparation method therefor |
| CN1314157A (en) * | 2000-03-20 | 2001-09-26 | 刘成才 | Traditional Chinese medicine for curing diabetes and kidney deficiency |
| CN101507757A (en) * | 2009-04-03 | 2009-08-19 | 谢正杰 | Compound Chinese medicine for treating diabetes |
| CN101632769A (en) * | 2008-07-25 | 2010-01-27 | 河北以岭医药研究院有限公司 | Chinese medicinal composition for regulating blood sugar and preparation method thereof |
| KR20130121385A (en) * | 2012-04-27 | 2013-11-06 | 주식회사 소리소 | A granule improved stock stability of anthocyanin pigment from mulberry, blueberry and s. chinensis baillon extracts and manufacturing method of the same |
| CN103816428A (en) * | 2014-03-26 | 2014-05-28 | 李常明 | Preparation for effectively treating diabetes mellitus |
-
2014
- 2014-10-15 CN CN201410557099.5A patent/CN105497205A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1225823A (en) * | 1998-02-12 | 1999-08-18 | 王钢柱 | Chinese medicine for treating diabetes and preparation method therefor |
| CN1314157A (en) * | 2000-03-20 | 2001-09-26 | 刘成才 | Traditional Chinese medicine for curing diabetes and kidney deficiency |
| CN101632769A (en) * | 2008-07-25 | 2010-01-27 | 河北以岭医药研究院有限公司 | Chinese medicinal composition for regulating blood sugar and preparation method thereof |
| CN101507757A (en) * | 2009-04-03 | 2009-08-19 | 谢正杰 | Compound Chinese medicine for treating diabetes |
| KR20130121385A (en) * | 2012-04-27 | 2013-11-06 | 주식회사 소리소 | A granule improved stock stability of anthocyanin pigment from mulberry, blueberry and s. chinensis baillon extracts and manufacturing method of the same |
| CN103816428A (en) * | 2014-03-26 | 2014-05-28 | 李常明 | Preparation for effectively treating diabetes mellitus |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107693713A (en) * | 2017-10-27 | 2018-02-16 | 北京昆达中医医学研究院 | A kind of Chinese herbal medicine drink of auxiliary hyperglycemic |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Münstedt et al. | Royal jelly reduces the serum glucose levels in healthy subjects | |
| Lachin et al. | Anti diabetic effect of cherries in alloxan induced diabetic rats | |
| US11166998B2 (en) | Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system | |
| Nair et al. | Evaluation of in vitro antidiabetic activity of selected plant extracts | |
| CN105920476B (en) | Traditional Chinese medicine composition for preventing and treating Alzheimer disease and preparation method thereof | |
| Banihani et al. | Fresh pomegranate juice decreases fasting serum erythropoietin in patients with type 2 diabetes | |
| SABASTINE et al. | Effect of cashew apple juice (Anacardium occidentale L.) on hematology and spleen of gentamicin induced injury in albino rats | |
| KR102041847B1 (en) | Composition for preventing, improving or treating depression and anxiety disorders comprising Fraxinus rhynchophylla extract as effective component | |
| KR102002168B1 (en) | Composition for preventing, ameliorating or treating depression and anxiety disorders comprising esculin as effective component | |
| Nassiri et al. | Effects of ginger on spermatogenesis in streptozotocin-induced diabetic rat | |
| Ogar et al. | Anti-hyperglycemic potential of Hyptis verticillata jacq in streptozotocin-induced diabetic rats | |
| Chukwuma et al. | Anti-diabetic and renal protective effect of the fruit juice of Citrus X Paradisi on alloxan induced diabetic male albino wistar rats | |
| CN105497205A (en) | Medicine for interventionally treating diabetes | |
| CN108463234A (en) | The glucose metabolism activator of astroglia | |
| KR20190003089A (en) | Composition for preventing, improving or treating depression and anxiety disorders comprising Bangpungtongseong-san extract as effective component | |
| CN101204573B (en) | Medicine foe diabetes mellitus | |
| CN104825632A (en) | Drug for intervention treatment of diabetic peripheral neuropathy (DPN) | |
| CN104758316A (en) | Pharmaceutical composition for preventing and curing diabetes itches | |
| CN102335347A (en) | Panax pseudo-ginseng and panax quinquefolium soft capsules | |
| Abubakar et al. | In vitro antidiabetic potentials of crude saponins extract from Leptodenia hastata and Adansonia digitata leaves | |
| EL-Tantawi et al. | Evaluation of the side effects of different doses of spirulina on various organs in rats: Biochemical, histological and histochemical assessment | |
| CN106265934A (en) | A kind of prevention and the pharmaceutical composition for the treatment of diabetes | |
| CN104352593B (en) | A kind of pharmaceutical composition for treating diabetes | |
| CN111643641B (en) | Food therapy formula for clearing heat, invigorating spleen and tonifying kidney and preparation method and application thereof | |
| Mohammadimanesh et al. | The comparative effect of different types of honey on levels of glucose, fructosamine and insulin in Streptozocin-induced diabetes in Wistar rats. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160420 |
|
| WD01 | Invention patent application deemed withdrawn after publication |